Biosynthesis and biological activity of leukotriene B5.
Several studies indicate that increased intake of eicosapentaenoic acid (EPA) in the diet may lead to decreased incidence of thrombotic events. Most investigators agree that this is achieved by competitively inhibiting the conversion of arachidonic acid (AA) to thromboxane A2 in the platelets. The effect of high EPA-intake on the formation of prostacyclin is less clear. However, EPA is a good substrate for lipoxygenase enzymes which results in formation of hydroperoxy- and hydroxy-acids, and, in some cases, leukotrienes. The biological activities of the leukotrienes derived from arachidonic acid suggest that they mediate or modulate some symptoms associated with inflammatory and hypersensitivity reactions. In order to clarify the possible effect of dietary manipulation on inflammatory processes, leukotriene B5 (LTB5) was prepared and its biological activities assessed. LTB5 was biosynthesized by incubation EPA with glycogen-elicited polymorphonuclear neutrophils (PMN) from rabbits in the presence of the divalent cation ionophore, A23187. The LTB5 was extracted from the incubate using mini-reverse phase extraction columns (Sep-pak) and purified by reverse-phase high pressure liquid chromatography (RP-HPLC). The purity of the product assessed by repeat RP-HPLC and straight phase (SP) HPLC was greater than 95%. Ultra-violet spectrophotometry of the product confirmed its purity and also provided assessment of the yield. The biological activity of LTB5 was assessed and compared with that of LTB4 in the following tests: aggregation of rat neutrophils, chemokinesis of human PMN, lysosomal enzyme release from human PMN and potentiation of bradykinin-induced plasma exudation. In all these tests, LTB5 was considerably less active (at least 30 times) than LTB4.
D000818:Animals; D000001:Calcimycin / Q000494:pharmacology; D002449:Cell Aggregation / Q000187:drug effects; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D002851:Chromatography, High Pressure Liquid; D003571:Cytochalasin B / Q000494:pharmacology; D015118:Eicosapentaenoic Acid / Q000031:analogs & derivatives; D005231:Fatty Acids, Unsaturated / Q000378:metabolism; D005966:Glucuronidase / Q000378:metabolism; D006801:Humans; D007975:Leukotriene B4 / Q000096:biosynthesis* / Q000302:isolation & purification / Q000494:pharmacology / Q000031:analogs & derivatives; D008247:Lysosomes / Q000201:enzymology; D051379:Mice; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology; D011817:Rabbits; D051381:Rats
D005231:Fatty Acids, Unsaturated; D007975:Leukotriene B4; D000001:Calcimycin; D003571:Cytochalasin B; C040212:leukotriene B5; D015118:Eicosapentaenoic Acid; D005966:Glucuronidase